Year: 2021

Trends in prevalence and outcomes of frailty in a Swiss university hospital: A retrospective observational study

Bonjour Thierry

Bonjour Thierry, 2021, Trends in prevalence and outcomes of frailty in a Swiss university hospital: A retrospective observational study

Originally published at: Thesis, University of Lausanne

Posted at the University of Lausanne Open Archive http://serval.unil.ch

Document URN: urn:nbn:ch:serval-BIB_6DD8B3A2F1686

Droits d’auteur
L’Université de Lausanne attire expressément l’attention des utilisateurs sur le fait que tous les documents publiés dans l’Archive SERVAL sont protégés par le droit d’auteur, conformément à la loi fédérale sur le droit d’auteur et les droits voisins (LDA). A ce titre, il est indispensable d’obtenir le consentement préalable de l’auteur et/ou de l’éditeur avant toute utilisation d’une oeuvre ou d’une partie d’une oeuvre ne relevant pas d’une utilisation à des fins personnelles au sens de la LDA (art. 19, al. 1 lettre a). A défaut, tout contrevenant s’expose aux sanctions prévues par cette loi. Nous déclinons toute responsabilité en la matière.

Copyright
The University of Lausanne expressly draws the attention of users to the fact that all documents published in the SERVAL Archive are protected by copyright in accordance with federal law on copyright and similar rights (LDA). Accordingly it is indispensable to obtain prior consent from the author and/or publisher before any use of a work or part of a work for purposes other than personal use within the meaning of LDA (art. 19, para. 1 letter a). Failure to do so will expose offenders to the sanctions laid down by this law. We accept no liability in this respect.
Trends in prevalence and outcomes of frailty in a Swiss university hospital: A retrospective observational study

THESE

préparée sous la direction du Professeur Gérard Waeber
avec la collaboration du Professeur Pedro-Manuel Marques-Vidal

et présentée à la Faculté de biologie et de médecine de
l’Université de Lausanne pour l’obtention du grade de

DOCTEUR EN MEDECINE

par

Thierry BONJOUR

Médecin diplômé de la Confédération Suisse
Originaire de Blonay (Vaud)

Lausanne
2021
Imprimatur

Vu le rapport présenté par le jury d'examen, composé de

Directeur de thèse
Prof. Gérard Waeber

Co-Directeur de thèse

Expert
Prof. Christophe Büla

Vice-Directeur de l'Ecole doctorale
Prof. John Prior

la Commission MD de l'Ecole doctorale autorise l'impression de la thèse de

Monsieur Thierry Bonjour

intitulée

Trends in prevalence and outcomes of frailty in a Swiss university hospital: A retrospective observational study

Lausanne, le 11 février 2021

pour Le Doyen
de la Faculté de Biologie et de Médecine

Monsieur le Professeur John Prior
Vice-Directeur de l'Ecole doctorale
RESEARCH PAPER

Trends in prevalence and outcomes of frailty in a Swiss university hospital: a retrospective observational study

Thierry Bonjour, Gérard Waebler, Pedro Marques-Vidal

Department of Medicine and Internal Medicine, Lausanne University Hospital (CHUV), Lausanne, Switzerland

Address correspondence to: Pedro Marques-Vidal, Office BH 10-642, Service de médecine interne, Centre hospitalier universitaire vaudois, Rue du Bugnon 46, 1011 Lausanne, Switzerland. Tel: (+41) 21 314 09 34; Email: Pedro-Manuel.Marques-Vidal@chuv.ch

Abstract

Background: Frailty complicates management and worsens outcomes. We assessed the prevalence, determinants and consequences of frailty among elderly patients in a hospital setting.

Design: Retrospective observational study in a Swiss university hospital.

Methods: 22,323 patients aged ≥65 years hospitalized between January 2009 and December 2017 at the internal medicine ward were included. Frailty was defined by the Hospital Frailty Risk Score (HFRS) and patients were categorized as low (HFRS < 5), intermediate (HFRS 5–15) and high (HFRS > 15) risk.

Results: Overall prevalence of intermediate and high risk of frailty was 43% and 20%, respectively; prevalence was higher in women and increased with age. Prevalence of high risk of frailty increased from 11.4% in 2009 to 31% in 2012, and decreased to 19.2% in 2017. After multivariable adjustment, frailty was associated with increased length of stay: average and (95% confidence interval) 11.9 (11.7–12.1), 15.6 (15.4–15.8) and 19.7 (19.3–20.1) days for low, intermediate and high risk, respectively, and increased likelihood of ICU stay: odds ratio (OR) and (95% CI) 1.57 (1.41–1.75) and 2.10 (1.82–2.42) for intermediate and high risk, respectively, p for trend < 0.001. Frailty was associated with increased likelihood of hospital costs > 70,000 CHF: OR and (95% CI) 3.46 (2.79–4.29) and 10.7 (8.47–13.6) for intermediate and high risk, respectively, p for trend < 0.001, and with a lower likelihood of complete cost coverage: OR and (95% CI) 0.70 (0.65–0.76) and 0.52 (0.47–0.58) for intermediate and high risk, respectively, p for trend < 0.001.

Conclusions: Frailty is a frequent condition among hospitalized patients and is associated with higher costs.

Keywords: frailty, patients, health costs, Switzerland, retrospective study, older people

Key Points

• Frailty trends is a retrospective study on 22,323 patients aged ≥65 years.
• Of these patients, 43% were at intermediate and 20% at high risk of frailty.
• High risk of frailty increased length of stay, hospital costs and risk of intensive care unit stay.

Introduction

It is estimated that by year 2050 circa two billion people aged over 65 years will populate the world [1]. In some parts of Switzerland, the number of people aged over 65 is expected to double, representing one-quarter of the total population [2]. This increase poses a considerable pressure in the hospital setting, where increasingly older and more frail patients are admitted. Frailty can be defined by a state of vulnerability following a stress and is a consequence of cumulative decline in multiple physiological systems eroding homeostatic reserve until relative minor stressor events trigger disproportionate changes in health status [3]. In 2005, Rockwood et al. [4] published the Clinical Frailty Scale (CFS), grading frailty
on a 7-point scale ranging from 1 (very fit) to 7 (severely frail). Although many other tools to assess frailty have been described since, there is still no gold standard for frailty detection [5]. This multiplicity of available tools has led to widely differing values for the prevalence of frailty, ranging from 10 to 23% among patients aged over 65 [6,7].

Frailty is an important and independent risk factor for mortality [8], lower quality of life [9], increased hospital length of stay (LOS) [10] and costs [11], increased risk of nursing home admission [10] and rehospitalisation [12]. This high burden of frailty on the health system raises the issue of a systematic screening of frailty in older people, the effectiveness of which is currently debated [13]. Indeed, the effectiveness of such a screening is dependent on the screening tool used, which should be easy to apply and with a high sensitivity and specificity. The tools cited earlier do not fulfil these criteria, for instance, the frailty phenotype [14] is time consuming and includes measurements not routinely used for patient assessment like gait speed or grip strength; the Clinical Frailty Scale [4] is dependent on clinical appreciation, and the Frailty Index [15] has not been validated in hospital settings. Recently, Gilbert et al. [16] proposed the Hospital Frailty Risk Score (HFRS) to assess frailty in the acute care setting. To our knowledge, the HFRS is the only tool developed for a hospital setting. Recently, the prognostic value of the HFRS has been validated on an independent patient population and confirmed the ability of the score to identify patients at risk of adverse outcomes [17].

Hence, we aimed to (1) evaluate the prevalence and the 9-year evolution of frailty (as defined by the HFRS) in patients aged ≥65 years hospitalised on the internal medicine ward of the Lausanne University Hospital (CHUV) and (2) study the association between frailty and LOS, in-hospital mortality, intensive care unit (ICU) stay, early readmissions and hospital costs. We hypothesised that the prevalence of frailty would increase and would be associated with all deleterious outcomes and increased costs.

Patients and methods

Setting

This is a retrospective study using medical information from the Department of Internal Medicine of the CHUV. The CHUV is one of the Swiss university hospitals (www.chuv.ch), and the internal medicine unit of the CHUV is the largest in Switzerland, with over 4,000 admissions per year. The CHUV serves both as an end-stage hospital and as a general hospital for the population of canton Vaud.

Participants

We included all patients aged 65 or more, hospitalised between January 2009 and December 2017. Over four out of five admissions to the internal medicine ward transit via the emergency department.

Methods

Coded data was extracted from the hospital medical records by an independent office in charge of data extraction and coding at the CHUV. The following information was extracted: gender, age, number of diagnoses at discharge (coded according to the 10th International Classification of Diseases of the World Health Organization—ICD-10), LOS (in days), stay in an ICU (yes/no), status at discharge (death, return home or institutionalised), 30-day, 90-day and 1-year mortality, and total and reimbursable costs. Mortality data was obtained from the population registries, which record the vital status of a person (i.e. alive/death) but not the cause of death.

We computed the Charlson risk score according to an algorithm optimised for Switzerland [18] and categorised the participants into 0, 1–2, 3–4 and 5+ as suggested in the original publication [19].

The rate of readmission was computed taking into account the 1st admission for each patient within the 2004–17 period, admissions occurring 30 days after the 1st one were considered.

Due to changes in the Swiss reimbursement system by the introduction of the Diagnosis Related Groups (DRG), reimbursable costs were obtained only for years 2012 onwards. Total costs were categorised into <70,000 and ≥70,000 Swiss franc (CHF); this limit was chosen as it is the approximated cost of 1 year of chronic haemodialysis in Switzerland [20]. The difference between total and reimbursable costs was computed and categorised as fully covered if the difference was ≥0. Cost of stay was further categorised according to the DRG criteria into lowlier (LOS below the low margin of LOS for the corresponding DRG), inlier (within the low and high margins of LOS for the corresponding DRG) or highlier (above the high margin of LOS for the corresponding DRG).

Risk of frailty

Risk of frailty was defined according to HFRS proposed by Gilbert et al. [16]. The HFRS is a sum of different ICD-10 codes, which are weighted according to their clinical impact. The weight for each condition is provided in Supplementary Table S1. For each admission, the HFRS was computed based on ICD codes and categorised into low (≤5), intermediate (5–15) and high (>15) risk.

Ethical statement

The Ethics Commission of Canton de Vaud (www.cer-vd.ch) approved the study protocol (decision No. 2018-01689 of 11 October 2018). The full decision of the CER-VD can be obtained from the authors upon request. The study was performed in agreement with the Helsinki declaration and its former amendments, and in accordance with the applicable Swiss legislation. No individual informed consent was deemed necessary.
Statistical analysis

Statistical analysis was performed using Stata version 16.1 for windows (Stata Corp, College Station, TX, USA). Descriptive results were expressed as number of participants (percentage) or as average± standard deviation (SD). Bivariate analyses were performed using chi-square test for qualitative variables and analysis of variance or Kruskal–Wallis test for continuous variables.

Trends in prevalence of intermediate and high risk of frailty were assessed using multinomial logistic regression and the results were expressed as multivariable-adjusted relative risk ratios and 95% confidence interval (95% CI). For categorical variables, multivariable analysis was conducted using logistic regression and results were expressed as odds ratio and 95% CI. For continuous variables, multivariable analysis was conducted using analysis of variance and results were expressed as multivariable-adjusted average and 95% CI. Due to the skewed distribution of LOS and health costs, negative binomial regression was performed. Survival analysis was conducted using Cox regression and results were expressed as hazard ratios and 95% CI. All multivariable models were adjusted on gender (man, woman), age group (65–74, 75–84, 85+), number of previous hospitalisations (continuous) and Charlson index categories (0, 1–2, 3–4, 5+). Further adjustments on year of discharge, ICU stay (yes, no) and LOS (quartiles) were performed whenever necessary. Trends within the different frailty groups were tested using the ‘contrast p.’ command of Stata.

As participants could be hospitalised several times during the study period, a 1st sensitivity analysis was performed considering only the 1st hospitalisation. As the HFRS uses data from the previous 2 years, a 2nd sensitivity analysis was performed considering only the period 2011–17. Due to the number of tests performed, statistical significance was assessed for a two-sided test with $P < 0.001$.

Results

Characteristics of patients admitted according to frailty categories

Overall, 22,323 admissions were included (52% women, mean ± SD age 80.2 ± 8.2 years). Prevalence of frailty, defined as an intermediate or high HFRS, was 63% (95% CI: 62.7–64.0), with 43% ($N = 9,656$) in the intermediate-risk and 20% ($N = 4,485$) in the high-risk groups.

The characteristics of the patients admitted overall and according to frailty category are summarised in Table 1. Patients at intermediate or high risk of frailty were more frequently women, were older, presented more frequently with a main diagnosis of gait problems, delirium and sepsis, and less frequently with a main diagnosis of acute myocardial infarction and chronic obstructive pulmonary disease than patients at low risk. Regarding types of disease, patients at intermediate or high risk of frailty presented more frequently with pneumonia, gait problems, delirium, sepsis, chronic kidney disease, diabetes and hypertension, and less frequently with a main diagnosis of acute myocardial infarction and chronic obstructive pulmonary disease than patients at low risk. Finally, patients at intermediate or high risk of frailty had a higher number of comorbidities and were more frequently in the 3–4 and 5+ categories of the Charlson index (Table 1).

Evolution of frailty between 2009 and 2017

The trends between 2009 and 2017 for prevalence of the intermediate- and the high-risk categories of frailty are represented in Figure 1. There was an increase in the prevalence of high-risk patients from 2009 to 2012, followed by a sharp decrease afterwards. This evolution was further confirmed after multivariable adjustment (Figure 2).

Association between frailty and LOS, ICU stay, mortality and costs

The bivariate associations between frailty categories and destination after hospitalisation, ICU stay, LOS, readmission, hospital costs, and 30-, 90-day and 1-year mortality are summarised in Table 2. Patients at intermediate or high risk of frailty were more frequently admitted to the ICU, spent more time in the ICU and were more frequently institutionalised after discharge than patients at low risk. Patients at high risk of frailty had a higher 30-day, 90-day and 1-year mortality than patients at low risk. Patients at intermediate or high risk had higher total and reimbursed costs, their stay was less frequently fully covered and they were more frequently highliers than patients at low risk.

The multivariable associations between frailty categories and ICU stay, LOS, readmission, hospital costs, and 30-, 90- and 1-year mortality are summarised in Supplementary Table S2. Overall, the results were similar to those from the bivariate analyses, except that the associations with 30-day mortality were no longer significant. Further adjusting on ICU stay and LOS led to similar findings, except that the differences regarding cost coverage were no longer significant (Supplementary Table S3). Finally, adjusting for number of previous hospitalisations showed frailty levels to be positively associated with 30-, 90- and 1-year mortality (Table 3).

Sensitivity analysis

The results of the analyses using only 1st admissions are summarised in Supplementary Tables S4–S6. On bivariate analysis, patients at intermediate or high risk of frailty were more frequently admitted to the ICU, spent more time in the ICU and were more frequently institutionalised after discharge than patients at low risk. No differences were found regarding 30- and 90-day mortality, whereas patients at intermediate or high risk of frailty had a higher 1-year mortality than patients at low risk. Patients at intermediate or high risk had a higher total and reimbursed costs, their stay was less frequently fully covered and they were more frequently
Table 1. Clinical characteristics overall and according to the different frailty risk categories, Lausanne University Hospital, Lausanne, Switzerland, 2009–17

<table>
<thead>
<tr>
<th></th>
<th>Total</th>
<th>Low</th>
<th>Intermediate</th>
<th>High</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>22,323</td>
<td>8,182</td>
<td>9,656</td>
<td>4,485</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Women (%)</td>
<td>11,579 (51.9)</td>
<td>4,000 (48.9)</td>
<td>5,139 (53.2)</td>
<td>2,440 (54.4)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Age (years)</td>
<td>80.2 ± 8.2</td>
<td>78.2 ± 8.1</td>
<td>81.0 ± 8.1</td>
<td>82.2 ± 7.8</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Age group (%)</td>
<td>65–74</td>
<td>2,121 (27.4)</td>
<td>2,950 (36.1)</td>
<td>2,340 (24.2)</td>
<td>831</td>
</tr>
<tr>
<td></td>
<td>75–84</td>
<td>8,621 (38.6)</td>
<td>3,170 (38.7)</td>
<td>3,699 (38.3)</td>
<td>1,752 (39.1)</td>
</tr>
<tr>
<td></td>
<td>85+</td>
<td>7,581 (34.0)</td>
<td>2,062 (25.2)</td>
<td>3,617 (37.5)</td>
<td>1,902 (42.4)</td>
</tr>
</tbody>
</table>

Main diagnosis (%)<0.001
- Heart failure
- Pneumonia
- Gait problems
- Delirium
- Sepsis
- Acute myocardial infarction
- COPD
- Diabetes
- Other

Presence of (%)<0.001
- Heart failure
- Pneumonia
- Gait problems
- Delirium
- Sepsis
- Acute myocardial infarction
- COPD
- Chronic kidney disease
- Diabetes
- Hypertension

Number of ICD-10 codes
- 0
- 1–2
- 3–4
- 5+

Charlson index categories (%)<0.001
- 0
- 1–2
- 3–4
- 5+

COPD, chronic obstructive pulmonary disease. Results are expressed as number of patients (column percentage) for categorical variables and as average ± standard deviation or median [interquartile range] for continuous variables. Between-group comparisons performed using chi-square for categorical variables and analysis of variance or Kruskal–Wallis test (‡) for continuous variables.

The results of the sensitivity analysis focusing on period 2011–17 are summarised in Supplementary Tables S7–S10. Prevalence of intermediate and high risk of frailty

highliers than patients at low risk (Supplementary Table S4). Most associations were confirmed after multivariable analysis (Supplementary Table S5). Further adjusting on ICU stay and LOS led to similar findings, except that 1-year mortality and the differences between total and reimbursed costs and cost coverage were no longer significant (Supplementary Table S6).
Frailty trends and health consequences

Figure 1. Trends in the prevalence of intermediate and high risk of frailty in the Department of Internal Medicine of the Lausanne University Hospital, 2009–17. Results are expressed as percentage.

Table 2. Bivariate analysis of the associations between frailty risk categories and different outcomes, Lausanne University Hospital, Lausanne, Switzerland, 2009–17

<table>
<thead>
<tr>
<th></th>
<th>Low</th>
<th>Intermediate</th>
<th>High</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>8,182</td>
<td>9,656</td>
<td>4,485</td>
<td></td>
</tr>
<tr>
<td>Length of stay (days)</td>
<td>9.5 [6.0; 15.0]</td>
<td>12 [7.9; 18.8]</td>
<td>13.9 [9.0; 21.9]</td>
<td>&lt;0.001‡</td>
</tr>
<tr>
<td>ICU stay (%)</td>
<td>663 (8.1)</td>
<td>984 (10.2)</td>
<td>537 (12.0)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>ICU stay (hours)</td>
<td>68 [28; 120]</td>
<td>97 [48; 184]</td>
<td>13 [61; 308]</td>
<td>&lt;0.001‡</td>
</tr>
<tr>
<td>Destination at discharge (%)</td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Deceased</td>
<td>655 (8.0)</td>
<td>783 (8.1)</td>
<td>486 (10.8)</td>
<td></td>
</tr>
<tr>
<td>Returned home</td>
<td>5,413 (66.2)</td>
<td>4,351 (45.1)</td>
<td>1,403 (31.3)</td>
<td></td>
</tr>
<tr>
<td>Institutionalised</td>
<td>2,111 (25.8)</td>
<td>4,517 (46.8)</td>
<td>2,595 (57.9)</td>
<td></td>
</tr>
<tr>
<td>Mortality (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30-day</td>
<td>911 (11.1)</td>
<td>1,066 (11.0)</td>
<td>628 (14.0)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>90-day</td>
<td>1,474 (18.0)</td>
<td>1,822 (18.9)</td>
<td>1,035 (23.1)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>1-year</td>
<td>2,471 (30.2)</td>
<td>3,222 (33.4)</td>
<td>1,856 (41.4)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Readmissions (N)</td>
<td>7,593</td>
<td>8,941</td>
<td>4,039</td>
<td></td>
</tr>
<tr>
<td>Rate</td>
<td>280 (3.7)</td>
<td>336 (3.8)</td>
<td>170 (4.2)</td>
<td>0.347</td>
</tr>
<tr>
<td>Costs (N)‡</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total (CHF)</td>
<td>11,161 [7,350; 17,946]</td>
<td>13,396 [8,918; 21,972]</td>
<td>15,303 [10,359; 26,924]</td>
<td>&lt;0.001‡</td>
</tr>
<tr>
<td>Reimbursed (CHF)</td>
<td>9,553 [7,604; 14,366]</td>
<td>10,516 [8,591; 16,518]</td>
<td>11,639 [9,419; 18,543]</td>
<td>&lt;0.001‡</td>
</tr>
<tr>
<td>Difference (CHF)</td>
<td>−846 [−4,491; 2,231]</td>
<td>−2,176 [−6,532; 1,439]</td>
<td>−3,216 [−8,548; 1,068]</td>
<td>&lt;0.001‡</td>
</tr>
<tr>
<td>Costs ≥70,000 CHF (N)</td>
<td>119 (1.5)</td>
<td>340 (3.5)</td>
<td>304 (6.8)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Full coverage (%)</td>
<td>2,204 (42.8)</td>
<td>2,143 (34.8)</td>
<td>923 (30.4)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>DRG category (%)</td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Lowlier</td>
<td>157 (3.1)</td>
<td>104 (1.7)</td>
<td>32 (1.1)</td>
<td></td>
</tr>
<tr>
<td>Inlier</td>
<td>4,036 (78.4)</td>
<td>4,612 (74.9)</td>
<td>2,094 (68.9)</td>
<td></td>
</tr>
<tr>
<td>Highlier</td>
<td>956 (18.6)</td>
<td>1,442 (23.4)</td>
<td>913 (30.0)</td>
<td></td>
</tr>
</tbody>
</table>

Results are expressed as number of patients (column percentage) for categorical variables and as average ± standard deviation or median and [interquartile range] for continuous variables. Between-group comparisons performed using chi-square for categorical variables and analysis of variance or Kruskal–Wallis test (‡) for continuous variables. †Among patients admitted to ICU. ‡Considering the 1st hospitalisation. †Data for period 2012–17.

was 43.1 and 22.0%, respectively. On bivariate analysis, patients at intermediate or high risk of frailty were more frequently admitted to the ICU, spent more time in the ICU, were more frequently institutionalised after discharge than patients at low risk, and had higher 30-day, 90-day and 1-year mortality than patients at low risk. Patients at intermediate or high risk had a higher total and reimbursed costs, their stay was less frequently...
Frail patients had a higher likelihood of being admitted in the ICU. These findings are in agreement with a recent study showing an association between frailty (as measured by the HFRS) and unplanned admission to the ICU [26]. A 2nd study also showed an association between frailty (as measured by Clinical Frailty Scale) and short-term mortality in older patients admitted to the ICU [27]. Conversely, another study found no significant association between frailty and adverse outcome after adjusting for disease severity [28]. However, patients in this last study had a very low mean HFRS (31), probably reflecting a severe selection of patients at ICU admission.
admission. Overall, our results strengthen the evidence of frailty as a risk factor for ICU admission.

Risk of frailty was positively associated with hospital costs, a finding in agreement with a study conducted in a community setting [11]. Risk of frailty was also associated with higher reimbursements, but the increase in reimbursements did not fully compensate the increase in hospital costs. Hence, patients at high risk of frailty led to higher financial losses to the hospital. Given the expected increase in the number of frail, older patients being admitted to the hospital, this finding is of great concern for hospital administrations who face a burden of additional costs. Hence, adequate screening and management of frail patients should be implemented to contain the rising associated costs.

Risk of frailty was not associated with hospital readmission, a finding consistent with a previous study [17], but not with another [22]. Still, in the last study, the association between frailty and readmission only held because early readmissions were included in a composite outcome [22]. Hence, our results do not support the hypothesis that risk of frailty is associated with increased risk of hospital readmission.

We found a significant association of frailty with 1-year mortality, whereas the association with 30-day and 90-day mortality was inconsistent. A positive association between frailty and 30-day mortality has been reported [17]. Several explanations can be put forward to explain this inconsistency. First, it could be explained by a much higher 30-day mortality (25 versus 12%) in the high-risk group in the study of Eckart et al. [17] than in the present study. Second, caring of high-risk patients could differ largely between hospitals or even between countries. Overall, our results suggest that frailty is related with 1-year mortality after discharge from hospital, whereas the association with short-term (30- and 90-day) mortality should be further checked.

**Strengths and limitations**

The main strengths of our study are the long survey period, which allowed to present trends and evaluation of status at discharge including institutionalisation.

This study also has some limitations. First, it is a monocentric, retrospective, observational study conducted in a Swiss tertiary hospital. Hence, the characteristics of the patients admitted (mostly multimorbid older patients) might not correspond to other settings. Still, the ageing of the population is occurring worldwide, and we believe that our results can be generalisable to most internal unit wards in developed countries. Second, as healthcare and reimbursement systems vary between countries, it is possible that the associations between HFRS and LOS or health costs might also change. Hence, it would be of interest that our findings be replicated in countries with different healthcare or reimbursement systems. Third, our definition of frailty may not reflect true frailty because of being based on comorbidities rather than on measurements such as grip strength. Still, they allow comparing our results with those of studies that used the same methodology [16,17].

Finally, the HFRS calculation is based on the ICD-10 codes from the discharge letter and not on the ICD-10 codes at the admission; furthermore, the coding of the conditions might vary between countries [29]. This can lead to an over- or under-estimation of the frailty risk and complicate between-country comparisons.

**Conclusion**

Frailty is frequent among hospitalised patients and is associated with higher hospital costs. The association between frailty and mortality awaits further investigation. This study demonstrates the feasibility of systematic screening for frailty in acute medicine. This could make it possible to improve the care of this population. Future studies investigating the correlation of HFRS with other validated scales in an acute care medicine setting such as CFS should be conducted.

**Supplementary Data:** Supplementary data mentioned in the text are available to subscribers in *Age and Ageing* online.

**Declaration of Conflicts of Interest:** None.

**Declaration of Sources of Funding:** None.

**References**


Received 24 August 2020; editorial decision 30 November 2020